secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001628280-23-038053
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

X4 Pharma: NDA accepted for mavorixafor in WHIM with PDUFA April 30, 2024; Q3 net loss $2.3M
--------------------------------------------------------------------------------

- FDA accepted NDA for once-daily oral mavorixafor in WHIM syndrome with Priority Review; PDUFA target April 30, 2024; eligible for Priority Review Voucher if approved.
- Ongoing Phase 2 chronic neutropenia data to be presented at ASH Dec 9-12, 2023; Phase 3 trial initiation expected 1H 2024.
- Q3 2023 cash, equivalents, and marketable securities totaled $142.7M; net loss of $2.3M (incl. $25.2M non-cash gain vs. $21.6M net loss in Q3 2022).
- Completed $115M debt facility with Hercules Capital; initial draw of $22.5M in August 2023.
- Appointed Christophe Arbet-Engels, MD, PhD as Chief Medical Officer in August 2023; added R. Keith Woods to Board of Directors in October 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000162828023038053/0001628280-23-038053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000162828023038053/xfor-20231109.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-038053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer